Cannabidiol (2) (Epidyolex®) – Dravet syndrome

1. Characteristics

Start date 15.10.2019
Resolution 02.04.2020
Limitation date 15.10.2020
INN Cannabidiol
Brand name Epidyolex®
Company GW Pharmaceuticals plc
ATC code N03AX24
DDD 0.7 g O
Therapeutic area Nervous system diseases ORPHAN
Reason for procedure New indication
Reassessed in: Cannabidiol (3, reassessment) (15.04.2021)
Specialties Bundling

SubgroupIndicationComparator
Patienten ab 2 Jahren mit Dravet-Syndrom – (Orphan drug)

9. Associated procedures

Resolution INN Brand name Indication Additional benefit
CannabidiolEpidyolex®Lennox-Gastaut syndrome
Cannabidiol (2) Epidyolex® Dravet syndrome


<< List of all resolutions